Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ann decrease » nn decrease (Expand Search), a decrease (Expand Search), gain decreased (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
_ ann » _ any (Expand Search), _ anc (Expand Search)
Showing 1 - 20 results of 2,821 for search '(( i large decrease ) OR ((( _ ann decrease ) OR ( c ((large decrease) OR (larger decrease)) ))))', query time: 0.53s Refine Results
  1. 1
    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. …”
    Save to List
    Saved in:
  2. 2
    Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i><sub><i>k</i></sub>; a–c and d–f decreasing porosity for outward and inward protection model respectively; <i>k</i><sub><i>L</i></sub> is head loss coefficient for inward protection model.

    Percentage of exhale flux penetrating through the mask fabric for different values of <i>c</i><sub><i>k</i></sub>; a–c and d–f decreasing porosity for outward and inward protection... by Akshay Anand (118579)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas

    Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas by Malena Sibaja Leyton (18400983)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i></sub> = 100,500,1000 (<i>kg</i>/<i>m</i><sup>2</sup> <i>s</i>) for outward protection (with nose clips) and inward protection model, respectively; the <i>k</i><sub><i>L</i></sub> for inward protection model is 0.5.

    Contribution of the through-mask leakages from the cavity and channel network distributed along the periphery of the mask; a–c and d–f are decreasing porosity <i>c</i><sub><i>k</i>... by Akshay Anand (118579)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Expression of lipid biosynthetic genes is decreased with polyamine depletion.

    Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

    Published 2024
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: